NASDAQ:TMDX TransMedics Group (TMDX) Stock Price, News & Analysis $140.49 -5.50 (-3.77%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$137.71▼$149.4750-Day Range$133.02▼$155.3852-Week Range$36.42▼$156.05Volume783,558 shsAverage Volume739,374 shsMarket Capitalization$4.63 billionP/E RatioN/ADividend YieldN/APrice Target$146.38 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get TransMedics Group alerts: Email Address TransMedics Group MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside4.2% Upside$146.38 Price TargetShort InterestBearish17.82% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.63Based on 8 Articles This WeekInsider TradingSelling Shares$30.09 M Sold Last QuarterProj. Earnings Growth43.21%From $0.81 to $1.16 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.19 out of 5 starsMedical Sector598th out of 936 stocksElectromedical Equipment Industry13th out of 22 stocks 2.4 Analyst's Opinion Consensus RatingTransMedics Group has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageTransMedics Group has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about TransMedics Group's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted17.82% of the outstanding shares of TransMedics Group have been sold short.Short Interest Ratio / Days to CoverTransMedics Group has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in TransMedics Group has recently decreased by 2.17%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldTransMedics Group does not currently pay a dividend.Dividend GrowthTransMedics Group does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TMDX. Previous Next 2.6 News and Social Media Coverage News SentimentTransMedics Group has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for TransMedics Group this week, compared to 5 articles on an average week.Search InterestOnly 5 people have searched for TMDX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows17 people have added TransMedics Group to their MarketBeat watchlist in the last 30 days. This is an increase of 240% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TransMedics Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $30,087,968.00 in company stock.Percentage Held by InsidersOnly 7.00% of the stock of TransMedics Group is held by insiders.Percentage Held by Institutions99.67% of the stock of TransMedics Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about TransMedics Group's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for TransMedics Group are expected to grow by 43.21% in the coming year, from $0.81 to $1.16 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TransMedics Group is -413.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TransMedics Group is -413.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTransMedics Group has a P/B Ratio of 33.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about TransMedics Group's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About TransMedics Group Stock (NASDAQ:TMDX)TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.Read More TMDX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TMDX Stock News HeadlinesJuly 18, 2024 | insidertrades.comTransMedics Group, Inc. (NASDAQ:TMDX) CEO Waleed H. Hassanein Sells 8,625 SharesJuly 24 at 7:43 AM | americanbankingnews.comTransMedics Group (TMDX) Scheduled to Post Quarterly Earnings on WednesdayJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 22, 2024 | americanbankingnews.comTransMedics Group (NASDAQ:TMDX) vs. Pixie Dust Technologies (NASDAQ:PXDT) Head-To-Head ContrastJuly 21, 2024 | ca.finance.yahoo.comTMDX.SG,0P0001QO8J,0 (TMDX.SG)July 20, 2024 | ca.finance.yahoo.comTMDX Dec 2024 95.000 putJuly 18, 2024 | prnewswire.comTransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)July 17, 2024 | prnewswire.comTransMedics to Report Second Quarter 2024 Financial Results on July 31, 2024July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 16, 2024 | americanbankingnews.comPiper Sandler Raises TransMedics Group (NASDAQ:TMDX) Price Target to $170.00July 8, 2024 | seekingalpha.comTransMedics Group Stock: Too Far, Too FastJuly 6, 2024 | 247wallst.com5 Growth Stocks Poised to Grow Faster than NVIDIA Next YearJune 28, 2024 | fool.comPrediction: These Could Be the Best-Performing Healthcare Stocks Through 2030June 21, 2024 | prnewswire.comTransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)June 20, 2024 | investorplace.comThe 3 Best Medical Device Stocks to Buy in June 2024June 17, 2024 | seekingalpha.comTransMedics: NOP, Logistics And Transport Are Key Growth Drivers But Stock Is PriceyMay 21, 2024 | seekingalpha.comTransMedics: Transportation Supporting GrowthMay 17, 2024 | prnewswire.comTransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)See More Headlines Receive TMDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TransMedics Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/30/2024Today7/26/2024Next Earnings (Confirmed)7/31/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical equipment Sub-IndustryMedical Equipment Current SymbolNASDAQ:TMDX CUSIPN/A CIK1756262 Webwww.transmedics.com Phone(978) 552-0900FaxN/AEmployees210Year FoundedN/APrice Target and Rating Average Stock Price Target$146.38 High Stock Price Target$175.00 Low Stock Price Target$117.00 Potential Upside/Downside+4.2%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($0.34) Trailing P/E RatioN/A Forward P/E Ratio173.44 P/E GrowthN/ANet Income$-25,030,000.00 Net Margins-3.43% Pretax Margin-3.92% Return on Equity7.95% Return on Assets1.61% Debt Debt-to-Equity Ratio3.18 Current Ratio9.72 Quick Ratio8.76 Sales & Book Value Annual Sales$241.62 million Price / Sales19.15 Cash Flow$0.13 per share Price / Cash Flow1,048.14 Book Value$4.20 per share Price / Book33.45Miscellaneous Outstanding Shares32,940,000Free Float30,631,000Market Cap$4.63 billion OptionableOptionable Beta1.98 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Waleed H. Hassanein M.D. (Age 56)Founder, President, CEO & Director Comp: $1.82MMr. Stephen Gordon (Age 56)CFO, Treasurer & Secretary Comp: $909.62kMr. Nicholas Corcoran (Age 41)Senior Vice President of Supply Chain & Operations Comp: $812.07kMr. Anil RanganathSenior VP, General Counsel & Corporate SecretaryDr. Tamer I. Khayal M.D. (Age 55)Chief Commercial Officer Comp: $900.11kMr. Mark AndersonSenior Director of Technology DevelopmentMs. Susan GoodmanVice President of Human ResourcesMs. Miriam C. Provost Ph.D. (Age 63)Vice President of Global Regulatory Affairs Comp: $535.93kMore ExecutivesKey CompetitorsMasimoNASDAQ:MASIIntegerNYSE:ITGRLivaNovaNASDAQ:LIVNCONMEDNYSE:CNMDSoleno TherapeuticsNASDAQ:SLNOView All CompetitorsInsiders & InstitutionsLiontrust Investment Partners LLPSold 231 shares on 7/26/2024Ownership: 0.095%EFG Asset Management North America Corp.Bought 2,343 shares on 7/26/2024Ownership: 0.064%Legato Capital Management LLCSold 86 shares on 7/26/2024Ownership: 0.042%Catalyst Capital Advisors LLCSold 975 shares on 7/26/2024Ownership: 0.020%RiverPark Advisors LLCSold 1,620 shares on 7/26/2024Ownership: 0.014%View All Insider TransactionsView All Institutional Transactions TMDX Stock Analysis - Frequently Asked Questions How have TMDX shares performed this year? TransMedics Group's stock was trading at $78.93 at the beginning of 2024. Since then, TMDX shares have increased by 78.0% and is now trading at $140.49. View the best growth stocks for 2024 here. How were TransMedics Group's earnings last quarter? TransMedics Group, Inc. (NASDAQ:TMDX) posted its earnings results on Tuesday, April, 30th. The company reported $0.35 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.40. The firm's revenue was up 132.9% on a year-over-year basis. What is Waleed Hassanein's approval rating as TransMedics Group's CEO? 17 employees have rated TransMedics Group Chief Executive Officer Waleed Hassanein on Glassdoor.com. Waleed Hassanein has an approval rating of 83% among the company's employees. When did TransMedics Group IPO? TransMedics Group (TMDX) raised $75 million in an initial public offering on Thursday, May 2nd 2019. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers. Who are TransMedics Group's major shareholders? Top institutional investors of TransMedics Group include Allspring Global Investments Holdings LLC (1.73%), Bank of New York Mellon Corp (1.28%), Vaughan Nelson Investment Management L.P. (0.80%) and Baillie Gifford & Co. (0.78%). Insiders that own company stock include James R Tobin, Waleed H Hassanein, Miriam Provost, Stephen Gordon, Nicholas Corcoran, Tamer I Khayal, John F Carey, David Weill, Edward M Basile, Stephanie Lovell, Laura Damme and Edwin M Kania Jr. View institutional ownership trends. How do I buy shares of TransMedics Group? Shares of TMDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of TransMedics Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that TransMedics Group investors own include Advanced Micro Devices (AMD), Roku (ROKU), AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), RTX (RTX) and Yamana Gold (AUY). This page (NASDAQ:TMDX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransMedics Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TransMedics Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
